1-20 of 22
Lida Pacaud
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ISB 2001: Accelerating Patient Benefits through Quantitative Systems Pharmacology (QSP) Guided First-in-Human (FIH) Starting Dose Selection

Vinu Menon, Lida Pacaud, Beata Holkova, Sunitha Gn, Andrew Garton, Maria Pihlgren, Tomomi Matsuura, Piet H van der Graft, Mario Perro, Cyril Konto
Journal: Blood
Blood (2024) 144 (Supplement 1): 6854.
https://doi.org/10.1182/blood-2024-209580
Published: 2024
Journal Articles

First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Hang Quach, Bradley Augustson, Hanlon Sia, Nishi Shah, Eben I Lichtman, Michaela Liedtke, Camille Martinet, Vinu Menon, Andrew Garton, Maria Pihlgren, Beata Holkova, Cyril Konto, Lida Pacaud, Amit Khot
Journal: Blood
Blood (2024) 144 (Supplement 1): 1026.
https://doi.org/10.1182/blood-2024-208189
Published: 2024
Journal Articles

Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

Binod Dhakal, Hang Quach, Phoebe Joy Ho, Andrew Spencer, Mark A. Schroeder, Peter Tan, Tara Cochrane, Hanlon Sia, Jeffrey A. Zonder, Camille Martinet, Dominique Duchesne, Andrew Garton, Vinu Menon, Beata Holkova, Cyril Konto, Lida Pacaud, Dickran Kazandjian
Journal: Blood
Blood (2024) 144 (Supplement 1): 3364.
https://doi.org/10.1182/blood-2024-209952
Published: 2024
Journal Articles

Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Prashant Kapoor, Don A. Stevens, Xavier Leleu, Karim Belhadj Merzoug, Lionel Karlin, Salomon Manier, Thomas Chalopin, Cyrille Hulin, Aurore Perrot, Jésus G Berdeja, Cristiana Costa Chase, Cyrille Touzeau, Philippe Moreau, Sanjay Mohan, Alexander Lesokhin, Carol Huff, David H. Vesole, Joshua Richter, Jeffrey Matous, Eileen Wolff, Tejas Shah, Jeppe Koch-Olsen, Andrew Garton, Vinu Menon, Sunitha Gn, Mario Perro, Eugene Zhukovsky, Cyril Konto, Lida Pacaud, Mohamad Mohty
Journal: Blood
Blood (2023) 142 (Supplement 1): 3339.
https://doi.org/10.1182/blood-2023-186664
Published: 2023
Journal Articles

A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma

Hanlon Sia, Vinu Menon, Andrew Garton, Eileen Wolff, Tejas Shah, Colleen Charpentier, Dominique Duchesne, Maria Pihlgren, Jeppe Koch-Olsen, Adam Drake, Mario Perro, Eugene Zhukovsky, Lida Pacaud, Cyril Konto
Journal: Blood
Blood (2023) 142 (Supplement 1): 3396.
https://doi.org/10.1182/blood-2023-187106
Published: 2023
Journal Articles

Integrated Preclinical Data Analysis of ISB 2001 Enables Optimal Starting Dose Selection for a First-in-Class Trispecific T Cell Engager Phase1 Study in Multiple Myeloma

Adam Drake, Maria Pihlgren, Vinu Menon, Daniela Pais, Laura Carretero-Iglesia, Jeremy Berret, Olivia Hall, Julie Macoin, Isabelle Gruber, Elodie Stainnack, Carole Estoppey, Cyrille Dreyfus, Girish Gudi, Tomomi Matsuura, Piet H van der Graft, Michael Dyson, Cyril Konto, Lida Pacaud, Ankita Srivastava, Eugene Zhukovsky, Mario Perro
Journal: Blood
Blood (2023) 142 (Supplement 1): 6574.
https://doi.org/10.1182/blood-2023-181546
Published: 2023
Journal Articles

Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Dickran Kazandjian, Hang Quach, Hanlon Sia, Phoebe Joy Ho, Andrew Spencer, Mark A. Schroeder, Binod Dhakal, Tara Cochrane, Jeffrey A. Zonder, Nancy Yi, Dominique Duchesne, Tejas Shah, Andrew Garton, Vinu Menon, Sunitha Gn, Stefano Sammicheli, Eugene Zhukovsky, Cyril Konto, Lida Pacaud, Peter Tan
Journal: Blood
Blood (2023) 142 (Supplement 1): 4707.
https://doi.org/10.1182/blood-2023-186241
Published: 2023
Journal Articles

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Clinical Trials & Observations
Adam D. Cohen, María-Victoria Mateos, Yael C. Cohen, Paula Rodriguez-Otero, Bruno Paiva, Niels W. C. J. van de Donk, Thomas Martin, Attaya Suvannasankha, Kevin C. De Braganca, Christina Corsale, Jordan M. Schecter, Helen Varsos, William Deraedt, Liwei Wang, Martin Vogel, Tito Roccia, Xiaoying Xu, Pankaj Mistry, Enrique Zudaire, Muhammad Akram, Tonia Nesheiwat, Lida Pacaud, Irit Avivi, Jesus San-Miguel
Journal: Blood
Blood (2023) 141 (3): 219–230.
https://doi.org/10.1182/blood.2022015526
Published: 2023
Includes: Supplemental data
Journal Articles

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

Nikhil C. Munshi, Bruno Paiva, Thomas Martin, Saad Usmani, Yi Lin, Jordan M. Schecter, Carolyn C. Jackson, Deepu Madduri, Enrique Zudaire, Tzu-min Yeh, J. Blake Bartlett, Lida Pacaud, Muhammad Akram, Dong Geng, Sundar Jagannath, Adam D. Cohen, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 4652–4654.
https://doi.org/10.1182/blood-2022-159141
Published: 2022
Journal Articles

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

Niels WCJ Van De Donk, Mounzer Agha, Adam D Cohen, Yael C Cohen, Sébastien Anguille, Tessa Kerre, Wilfried W.H. Roeloffzen, Jordan M Schecter, Kevin C De Braganca, Carolyn C Jackson, Helen Varsos, Pankaj Mistry, Tito Roccia, Xiaoying Xu, Katherine Li, Enrique Zudaire, Christina Corsale, Muhammad Akram, Dong Geng, Lida Pacaud, Pieter Sonneveld, Sonja Zweegman
Journal: Blood
Blood (2022) 140 (Supplement 1): 7536–7537.
https://doi.org/10.1182/blood-2022-159169
Published: 2022
Journal Articles

Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Myeloma Patients Undergoing BCMA-CAR-T: An Exploratory Analysis from CARTITUDE-1

Karen Sweiss, Pritesh Patel, Janet Guo, Kyeongmin Kim, Jordan M Schecter, Christina Y Sheng, Dawei Song, Xiaoying Xu, Yaming Su, Weirong Wang, Deepu Madduri, Carolyn C Jackson, Enrique Zudaire, Tzu-min Yeh, Tito Roccia, Dong Geng, Lida Pacaud, Douglas W Sborov, Mitch A Phelps, Craig C Hofmeister
Journal: Blood
Blood (2022) 140 (Supplement 1): 4323–4324.
https://doi.org/10.1182/blood-2022-159501
Published: 2022
Journal Articles

Characteristics and Outcomes in Patients with Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma Treated with 1-3 Prior Lines of Therapy: Analysis of the Individual Patient-Level Data from Daratumumab Clinical Trials

Binod Dhakal, Hermann Einsele, Jordan M Schecter, Tito Roccia, William Deraedt, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, Kaitlyn Connors, Keqin Qi, Anil Londhe, Robin Carson, Jennifer Voelker, Patricia Cost, Satish Valluri, Erika Florendo, Lida Pacaud, Kwee Yong
Journal: Blood
Blood (2022) 140 (Supplement 1): 4320–4322.
https://doi.org/10.1182/blood-2022-159151
Published: 2022
Journal Articles

Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy

Adam D. Cohen, María-Victoria Mateos, Yael C. Cohen, Paula Rodriguez Otero, Bruno Paiva, Niels W.C.J. Van De Donk, Thomas Martin, Attaya Suvannasankha, Christina Corsale, Jordan M. Schecter, Kevin C. De Braganca, Carolyn C. Jackson, Helen Varsos, William Deraedt, Tito Roccia, Pankaj Mistry, Xiaoying Xu, Katherine Li, Enrique Zudaire, Muhammad Akram, Lida Pacaud, Irit Avivi, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 4646–4648.
https://doi.org/10.1182/blood-2022-158563
Published: 2022
Journal Articles

DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study ( EM agine/CARTITUDE-6)

Mario Boccadoro, Jesús San-Miguel, Kenshi Suzuki, Niels W.C.J. Van De Donk, Gordon Cook, Andrzej Jakubowiak, Deepu Madduri, Salma Afifi, An-Sofie Stevens, Jordan M. Schecter, William Deraedt, Steven Kuppens, Pankaj Mistry, Lida Pacaud, Erika Florendo, Annemiek Broijl, Francesca Gay, Roberto Mina, Leo Rasche, Philippe Moreau, María-Victoria Mateos, Hermann Einsele, Pieter Sonneveld
Journal: Blood
Blood (2022) 140 (Supplement 1): 4630–4632.
https://doi.org/10.1182/blood-2022-157021
Published: 2022
Journal Articles

Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)

Dominik Dytfeld, Binod Dhakal, Mounzer Agha, Salomon Manier, Michel Delforge, Steven Kuppens, Salma Afifi, William Deraedt, Agne Taraseviciute-Morris, Jordan M. Schecter, Jane Gilbert, Fevzi Yalniz, Erika Florendo, Lida Pacaud, Vania Hungria, Saad Z. Usmani, Maria-Victoria Mateos
Journal: Blood
Blood (2021) 138 (Supplement 1): 1835.
https://doi.org/10.1182/blood-2021-146210
Published: 2021
Journal Articles

Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis

Andrzej Jakubowiak, Saad Z. Usmani, Jesus G. Berdeja, Mounzer Agha, Adam D Cohen, Parameswaran Hari, Jordan M. Schecter, Deepu Madduri, Tzu-Min Yeh, Yunsi Olyslager, Arnob Banerjee, Carolyn C. Jackson, Alicia Allred, Enrique Zudaire, William Deraedt, Changwei Zhou, Dong Geng, Lida Pacaud, Yi Lin, Thomas Martin, Sundar Jagannath
Journal: Blood
Blood (2021) 138 (Supplement 1): 3938.
https://doi.org/10.1182/blood-2021-146069
Published: 2021
Journal Articles

Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2

Yael C. Cohen, Adam D Cohen, Michel Delforge, Jens Hillengass, Hartmut Goldschmidt, Katja Weisel, Marc-Steffen Raab, Christof Scheid, Jordan M. Schecter, Kevin C. De Braganca, Helen Varsos, Tzu-min Yeh, Liwei Wang, Martin Vogel, Christina Corsale, Muhammad Akram, Lida Pacaud, Tonia Nesheiwat, Mounzer Agha, Hermann Einsele
Journal: Blood
Blood (2021) 138 (Supplement 1): 3866.
https://doi.org/10.1182/blood-2021-146072
Published: 2021
Journal Articles

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

Thomas Martin, Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Deepu Madduri, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Yi Lin, Sundar Jagannath
Journal: Blood
Blood (2021) 138 (Supplement 1): 549.
https://doi.org/10.1182/blood-2021-146060
Published: 2021
Journal Articles

Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study

Maria-Victoria Mateos, Katja Weisel, Thomas Martin, Jesús G. Berdeja, Andrzej Jakubowiak, A. Keith Stewart, Sundar Jagannath, Yi Lin, Joris Diels, Francesca Ghilotti, Nolen J Perualila, Jedelyn Cabrieto, Benjamin Haefliger, Nichola Erler-Yates, Clare Hague, Carolyn C. Jackson, Vadim Strulev, Tonia Nesheiwat, Lida Pacaud, Philippe Moreau, Hermann Einsele
Journal: Blood
Blood (2021) 138 (Supplement 1): 550.
https://doi.org/10.1182/blood-2021-146200
Published: 2021
Journal Articles

CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy

Niels W.C.J. Van de Donk, Michel Delforge, Mounzer Agha, Adam D Cohen, Yael C Cohen, Jens Hillengass, Sebastien Anguille, Tessa Kerre, Wilfried Roeloffzen, Jordan M. Schecter, Kevin C. De Braganca, Helen Varsos, Liwei Wang, Martin Vogel, Enrique Zudaire, Christina Corsale, Muhammad Akram, Dong Geng, Tonia Nesheiwat, Lida Pacaud, Pieter Sonneveld, Sonja Zweegman
Journal: Blood
Blood (2021) 138 (Supplement 1): 2910.
https://doi.org/10.1182/blood-2021-146074
Published: 2021